AEM Holdings Faces Patent Infringement Allegations from Advantest: What Investors Must Know

Key Points From the Announcement

• Advantest Test Solutions, Inc. has filed a patent infringement lawsuit against AEM Holdings Ltd. and its subsidiaries in the U.S. District Court for the Southern District of California.
• The complaint alleges infringement of U.S. Patent Nos. 11,674,999 and 12,320,841, which pertain to a specific wafer level test system.
• AEM strongly denies these allegations, stating that the patented technology is “not practiced by AEM.”
• AEM has engaged U.S. legal counsel and asserts the claims are without merit.
• This legal action follows a previously settled arbitration between the parties, resolved on 28 July 2023.
• The company emphasizes that the new lawsuit does not impact its business operations, existing products, or customer service.
• Revenue guidance for 2H 2025 remains unchanged as per the announcement on 13 August 2025.
• AEM commits to updating shareholders on any material developments.
• Investors are urged to exercise caution in trading and consult professional advisors if in doubt.

In-Depth Analysis for Investors

AEM Holdings Ltd. has been named in a patent infringement lawsuit by Advantest Test Solutions, Inc., targeting not only the parent company but also its key subsidiaries: AEM Singapore Pte. Ltd. and AEM Americas, Inc. The lawsuit was filed in the U.S. District Court for the Southern District of California and concerns patents related to a specific wafer level test system—technology which AEM claims is not utilized in any of its current offerings.

This legal dispute comes on the heels of a previous arbitration between the two companies, which was settled in July 2023. The recurrence of legal action from Advantest may signal ongoing tensions between the two industry players. However, AEM has responded swiftly, engaging U.S. legal counsel and presenting a strong denial of the allegations, underscoring its own sizable patent portfolio and ongoing respect for intellectual property rights.

Crucially for shareholders, AEM has stated that this lawsuit will have no effect on its business operations, product lineup, or ability to serve customers. The board has reaffirmed their revenue guidance for the second half of 2025, providing a measure of assurance to the market during this period of legal uncertainty.

Despite the company’s confident tone, investors should be alert to the potential for headline risk and the possibility of legal costs or disruptions should the matter escalate. The management’s commitment to regular updates is positive, but the situation remains fluid, and legal disputes of this nature can sometimes create short-term volatility in share prices, even if the underlying business is unaffected.

The announcement closes with a warning for both shareholders and potential investors to exercise caution when dealing in AEM securities and to seek advice from professional advisors if they have any doubts about the implications of this news.

Potential Price-Sensitive Factors

• Renewed legal conflict with a major competitor (Advantest) could impact investor sentiment.
• Outcome of U.S. patent litigation may influence future business operations or financials, depending on court findings or settlements.
• Unchanged revenue guidance for 2H 2025 provides some reassurance, but ongoing legal proceedings could introduce future uncertainties.
• Any significant developments or adverse rulings could affect AEM’s share price and should be closely monitored.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors are advised to perform their own due diligence and consult independent financial advisors before making investment decisions. The author and publisher accept no liability for any losses incurred based on the information provided above.

View AEM SGD Historical chart here